23 May 2013
Keywords: shire, mmx, mesalazine, performs, well, uc, studies
Article | 13 November 2006
UK-based drugmaker Shire says that data from trials of its drug MMX mesalazine, a once-daily oral treatment for mild-to-moderate ulcerative
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
13 November 2006
© 2013 thepharmaletter.com